계명대학교 의학도서관 Repository

Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study

Metadata Downloads
Author(s)
Myungsun ShimJong Keun KimWoo Jin BangYong Seong LeeSung Tae ChoJin Seon ChoKwan Joong JooJae Seog HyunByung Hoon KimJong Bok LeeYoung Jin SeoCheol Young Oh
Keimyung Author(s)
Kim, Byung Hoon
Department
Dept. of Urology (비뇨의학)
Journal Title
Investigative and Clinical Urology
Issued Date
2020
Volume
61
Issue
6
Keyword
Muscarinic antagonistsProstatic hyperplasiaTreatment outcomeUrinary bladderoveractive
Abstract
Purpose:
To analyze the efficacy and safety of standard-dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms showing poor efficacy after low-dose antimuscarinics.

Materials and Methods:
We retrospectively reviewed the data of 566 male patients aged ≥40 with OAB symptoms between January 2017 and June 2018. They were treated with low-dose antimuscarinics for at least 4 weeks and showed poor efficacy; therefore, they were switched to standard dose antimuscarinic treatment (5 mg of solifenacin) for ≥12 weeks. The international prostate symptom score (IPSS) and overactive bladder symptom score (OABSS) at baseline (V0), 4 weeks (V1), and 12 weeks (V2) were analyzed. Post void residual urine volume (PVR) was also recorded.

Results:
The median age, body mass index, and prostate-specific antigen levels were 69.0 years, 24.2 kg/m2, and 1.24 ng/dL, respectively. The mean value of the total IPSS and OABSS significantly decreased between V0 and V2 (from 16.73 to 13.69 and 7.33 to 5.34, respectively, all p<0.001). All component scores from each questionnaire demonstrated a significant decrease except for numbers three and six on the IPSS questionnaire. PVR was increased from V0 to V2 (36.40 to 68.90 mL, p=0.015). Four and nine patients experienced constipation and thirst, respectively, and all adverse effects were graded as ≤2.

Conclusions:
Standard dose antimuscarinic treatment using solifenacin (5 mg) may be a safe and effective treatment for patients with OAB symptoms refractory to low-dose antimuscarinic treatment.
Keimyung Author(s)(Kor)
김병훈
Publisher
School of Medicine (의과대학)
Citation
Myungsun Shim et al. (2020). Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study. Investigative and Clinical Urology, 61(6), 600–606. doi: 10.4111/icu.20200053
Type
Article
ISSN
2466-054X
Source
https://icurology.org/search.php?where=aview&id=10.4111/icu.20200053&code=2020ICU&vmode=FULL
DOI
10.4111/icu.20200053
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42844
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.